Search

©2018 Livzon  粤ICP备05025993号   Support:300.cn

Address: No. 38 Chuangye North Road, Jinwan District, Zhuhai, Guangdong, P.R.China Tel: +86 756 8135888

Overseas Markets
>
>
Overseas Specialty Products
>
Leuprorelin Acetate Microspheres for Injection

Leuprorelin Acetate Microspheres for Injection

[Product Name]

Leuprorelin Acetate Microspheres for Injection.

[Composition]

Main ingredients: copolymer of leuprorelin acetate and glycolide lactide (25:75), gelatin, D-mannitol.

[Indication]

1. Endometriosis

2.Hysteromyoma reduce and/or improve hysteromyoma accompanied by hypermenorrhea, hypogastralgia, back pain and anaemia and etc.

3. Premenopausal breast cancer with estrogen receptor positive.

4. Prostate cancer.

5. Central precocious puberty.

[Dosage and Administration]

1. Endometriosis: subcutaneous injection. Generally, once every four weeks for adult with 3.75 mg each time. Initial dose should begin from 1-5 days of menstrual period.

2. Hysteromyoma: subcutaneous injection. Generally, once every four weeks for adult with 1.88 mg each time. But patients with overweight or uterus increased significantly should be injected with 3.75 mg. Initial dose should begin from 1-5 days of menstrual period.

3. Prostate cancer, premenopausal breast cancer with estrogen receptor positive: subcutaneous injection. Generally, once every four weeks for adult with 3.75 mg each time.

4. Central precocious puberty: subcutaneous injection. Generally, once every four weeks with 30μg/kg each time, it can be increased to 90μg/kg according to the clinical symptoms of patients.

Before injection, this product should be fully suspended with 2 ml solvent. Pay attention to no foam during the suspension.

[How Supplied]

Injection vial, 3.75mg, 1 vial/box (1 vial+2 ml suspending agent).

[Storage Condition]

Protect from light and keep tightly sealed in a cool place (store below 20 0C). 

[Shelf Life]

24 months.

没有此类产品
Corresponding parameter set not found, please add it in property template of background
暂未实现,敬请期待
暂未实现,敬请期待